glp 1 and mash Incretin-based therapies in MASLD/MASH: from GLP-1 receptor agonists to dual triple agonists Beyond glucagon-like peptide-1: The promise

[DOI] [PubMed] [Google Scholar] 27.Ratamess N.A., Kraemer W.J., Volek J.S., Maresh C.M., VanHeest J.L., Sharman M.J., Rubin M.R., French D.N., Vescovi J.D., Silvestre R., et al

To view or add a comment, sign in 4,640 followers

Liver diseases reduce hepatocytes and increase the need for hepatocyte proliferation, thereby promoting up-regulation of c-Met and/or HGF

The Good Trade readers get an exclusive 20% off on GLP-1 Up The Good Trade Partner 2

This ensures accurate dosing and avoids errors

These findings indicate that PGK1 is not only a regulator of glycolytic flux but also a central hub linking glucose metabolic reprogramming to adaptive immune responses in myocarditis